8-K: Celcuity Reports Strong Q3 Clinical & Financial Progress

Celcuity Inc. announced positive Phase 3 VIKTORIA-1 trial results for gedatolisib in breast cancer, regulatory progress, and a strengthened balance sheet, despite increased operating expenses in Q3 2025.

Summary

• Presented detailed efficacy and safety results from the PIK3CA wild-type (WT) cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress.
• The gedatolisib-triplet (gedatolisib, fulvestrant, and palbociclib) reduced the risk of disease progression or death by 76% (Hazard Ratio of 0.24) compared to fulvestrant, with a median progression free survival (PFS) of 9.3 months versus 2.0 months.
• The gedatolisib doublet (gedatolisib and fulvestrant) reduced the risk of disease progression or death by 67% (Hazard Ratio of 0.33) compared to fulvestrant, with a median PFS of 7.4 months versus 2.0 months.
• Completed enrollment of the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial, with topline data expected in late Q1 2026 or during Q2 2026.
• Submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for gedatolisib, based on data from the PIK3CA WT cohort, is on track to be completed during the fourth quarter of 2025, and was accepted under the Real-Time Oncology Review (RTOR) program.
• Updated clinical results from the Phase 1b portion of a clinical trial evaluating gedatolisib in combination with Nubeqa (darolutamide) in men with metastatic castration resistant prostate cancer (mCRPC) showed a six-month radiographic PFS (rPFS) rate of 67% and median rPFS of 9.1 months for both arms combined.
• Net proceeds from a concurrent public offering in July 2025 were $287 million.
• The senior secured term loan facility was increased to $500 million, and an additional $30 million was drawn, providing net proceeds of $27.8 million.
• Investors exercised warrants in the third quarter of 2025, generating cash proceeds of $12.8 million.
• Total operating expenses for the third quarter of 2025 were $42.8 million, up from $30.1 million in the prior-year period.
• Net loss for the third quarter of 2025 was $43.8 million, or $0.92 loss per share, compared to a net loss of $29.8 million, or $0.70 loss per share, for the third quarter of 2024.
• Cash, cash equivalents and short-term investments totaled $455.0 million at September 30, 2025.
• Expect cash, cash equivalents, investments and drawdowns on the debt facility to fund operations through 2027.

Sentiment

Score: 9

Explanation: The filing reports highly positive Phase 3 clinical trial results for its lead candidate, gedatolisib, demonstrating significant efficacy and safety in a high-need patient population. Regulatory progress is strong with FDA RTOR acceptance and NDA submission on track. The company has also substantially strengthened its financial position through successful capital raises, extending its cash runway through 2027. While operating expenses and net loss increased, these are expected for a clinical-stage biotech nearing potential commercialization and are well-supported by the robust financing.

Positives

• Positive topline data for both primary endpoints of the PIK3CA WT cohort of the Phase 3 VIKTORIA-1 clinical trial, demonstrating potential for practice-changing results in HR+, HER2advanced breast cancer.
• Gedatolisib-triplet reduced the risk of disease progression or death by 76% (HR 0.24) with a median PFS of 9.3 months, an incremental improvement of 7.3 months over fulvestrant.
• Gedatolisib doublet reduced the risk of disease progression or death by 67% (HR 0.33) with a median PFS of 7.4 months, an incremental improvement of 5.4 months over fulvestrant.
• The gedatolisib regimens were generally well tolerated with mostly low-grade treatment-related adverse events (TRAEs) and low discontinuation rates (2.3% for triplet, 3.1% for doublet).
• The FDA accepted the company's request to submit an NDA for gedatolisib under the Real-Time Oncology Review (RTOR) program, potentially expediting the review process.
• Successful concurrent public offering generated $287 million in net proceeds, significantly strengthening the balance sheet.
• The senior secured term loan facility was upsized to $500 million, with an additional $30 million drawn, further enhancing capital structure and funding for commercial launch preparations.
• Warrant exercises generated an additional $12.8 million in cash proceeds.
• Strong cash, cash equivalents and short-term investments of $455.0 million at September 30, 2025.
• Expected funding of operations through 2027, providing a solid cash runway.

Negatives

• Total operating expenses increased to $42.8 million in Q3 2025 from $30.1 million in Q3 2024, representing a 42% increase.
• Research and development (R&D) expenses increased by $7.3 million to $34.9 million in Q3 2025, primarily due to increased employee, consulting, and clinical trial expenses.
• General and administrative (G&A) expenses increased by $5.4 million to $7.9 million in Q3 2025, largely driven by increased employee and consulting expenses, including non-cash stock-based compensation.
• Net loss for Q3 2025 was $43.8 million ($0.92 loss per share), a larger loss compared to $29.8 million ($0.70 loss per share) in Q3 2024.
• Net cash used in operating activities for Q3 2025 was $44.8 million, a significant increase from $20.6 million in Q3 2024.

Risks

• Clinical results are based on an ongoing analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial.
• Unforeseen delays in clinical trials.
• Unforeseen delays in the planned NDA for gedatolisib.
• Ability to obtain and maintain regulatory approvals to commercialize gedatolisib.
• Market acceptance of gedatolisib.
• Development of therapies and tools competitive with gedatolisib.
• Ability to access capital upon favorable terms.

Future Outlook

Celcuity expects to complete the New Drug Application (NDA) submission for gedatolisib (PIK3CA WT cohort) during the fourth quarter of 2025. Topline data for the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is anticipated in late Q1 2026 or during Q2 2026. The company projects that its current cash, cash equivalents, investments, and available drawdowns on its debt facility will fund operations through 2027.

Management Comments

• "We made significant clinical and regulatory progress in the third quarter." Brian Sullivan, CEO and co-founder of Celcuity.
• "At the ESMO Congress, we presented potentially practice-changing safety and efficacy results for the gedatolisib regimens from the PIK3CA wild-type cohort of our Phase 3 VIKTORIA-1 trial at a late breaking oral presentation." Brian Sullivan.
• "We remain on track to submit the New Drug Application for gedatolisib later this year based on data from the PIK3CA wild-type cohort." Brian Sullivan.
• "There is an urgent need for more efficacious therapies than those currently available for patients with HR+, HER2advanced breast cancer who have received prior treatment with a CDK4/6 inhibitor." Brian Sullivan.
• "With our strengthened balance sheet, and unprecedented efficacy results in this patient population, we are well positioned to bring gedatolisib to patients should we get FDA approval." Brian Sullivan.

Industry Context

The announcement highlights the critical unmet need for more effective therapies for patients with HR+, HER2advanced breast cancer whose disease has progressed after prior treatment with a CDK4/6 inhibitor. Gedatolisib's strong efficacy results, particularly the significant reduction in the risk of disease progression or death and extended median PFS, position it as a potentially 'practice-changing' therapy in this specific, high-need patient population. This could significantly disrupt the current treatment landscape and offer a new standard of care, impacting competitors in the advanced breast cancer market. The promising Phase 1b data for mCRPC also suggests potential expansion into other oncology indications.

Comparison to Industry Standards

• The filing states that the results demonstrate the potential for the gedatolisib regimens to be 'practice changing' for patients with HR+, HER2ABC who have received prior treatment with a CDK4/6 inhibitor, implying superior efficacy compared to current standard of care (e.g., fulvestrant alone, which showed 2.0 months median PFS).
• The CEO explicitly mentions 'unprecedented efficacy results in this patient population,' suggesting a high bar compared to existing or investigational therapies for HR+, HER2advanced breast cancer patients post-CDK4/6 inhibitor treatment.
• No specific comparable companies or projects are named in the filing for direct numerical comparison, but the language strongly implies outperformance against current treatment options for this patient group.

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical trial results, potential for FDA approval, strengthened balance sheet, and extended cash runway, which significantly de-risks the company's future prospects.
• Patients (HR+, HER2ABC): Highly positive impact as gedatolisib shows potential to be a 'practice-changing' therapy, offering significantly improved progression-free survival compared to existing treatments for those who have progressed on CDK4/6 inhibitors.
• Patients (mCRPC): Potential positive impact from promising updated Phase 1b study results, suggesting gedatolisib in combination with darolutamide is generally well tolerated and shows encouraging rPFS rates.
• Employees: Positive impact due to increased R&D and G&A expenses related to employee and consulting expenses, including commercial headcount additions, indicating company growth and potential for future commercialization.
• Creditors (Innovatus Capital Partners, Oxford Finance LLC): Positive impact from the amendment to the term loan facility, indicating continued partnership and confidence in the company's progress and financial stability.

Next Steps

• Completion of the New Drug Application (NDA) submission for gedatolisib (PIK3CA WT cohort) to the FDA during the fourth quarter of 2025.
• Anticipated topline data for the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial in late Q1 2026 or during Q2 2026.
• Continued enrollment for VIKTORIA-2, a Phase 3 clinical trial evaluating gedatolisib as a first-line treatment for patients with HR+/HER2ABC.
• Ongoing Phase 1/2 clinical trial (CELC-G-201) evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer.
• Commercial launch preparations for gedatolisib, pending FDA approval.

Key Dates

Recommendation

The filing presents exceptionally strong Phase 3 clinical data for gedatolisib in a high-need breast cancer population, demonstrating 'practice-changing' potential with significantly extended progression-free survival. The FDA's acceptance into the Real-Time Oncology Review program signals a potentially expedited path to market. Furthermore, the company has substantially bolstered its financial position through successful capital raises, extending its cash runway through 2027, which significantly de-risks its operations and commercialization efforts. While expenses are increasing, this is expected for a company nearing a potential drug launch. The combination of compelling efficacy, regulatory acceleration, and robust financing makes this a highly attractive investment opportunity.

Keywords

Celcuity, CELC, biotechnology, oncology, targeted therapies, gedatolisib, PIK3CA, VIKTORIA-1, breast cancer, HR+ HER2ABC, mCRPC, prostate cancer, FDA, NDA, RTOR, clinical trial, Phase 3, financial results, Q3 2025, operating expenses, net loss, cash position, capital raise, convertible notes, term loan